Skip to main content
    P

    Prime Medicine, Inc. Common Stock (PRME)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.19
    -0.08 (-1.87%)

    Market Cap: $949.85M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Prime Medicine, Inc. Common Stock (PRME) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Prime Medicine, Inc. Common Stock reported revenue of $4.63M for the fiscal year ended Dec 31, 2025, up 55.3% from the year before. That year, net income was -$201.14M with a net margin of -4342.4%, operating cash flow was -$162.56M and free cash flow was -$167.09M. The quarter ended Sep 30, 2026 had revenue of $4.21M and net income of -$39.04M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue fell from $5.21M, a compound annual decline of 2.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.63M+55.3%100.0%-4498.1%-4342.4%
    Dec 2024$2.98MN/A100.0%-6787.4%-6566.6%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$5.21MN/A100.0%-17.9%-65.5%
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$4.63M$2.98M$0$0$0$5.21MN/A
    Cost of revenue$0$0$0$0$0$0$2.76M
    Gross profit$4.63M$2.98M$0$0$0$5.21M-$2.76M
    Research and development$160.64M$155.29M$147.91M$86.72M$70.55M$2.98M$920.00K
    Operating income-$208.35M-$202.47M-$204.79M-$116.54M-$84.47M-$932.00K-$2.17M
    Net income-$201.14M-$195.88M-$198.13M-$121.82M-$165.37M-$3.41M-$2.53M
    EBITDA-$199.91M-$196.37M-$199.98MN/AN/AN/A-$2.17M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$4.21M$1.15M$856.00K$838.00K$1.23M$1.11M$1.45M$2.18M$209.00K$0$591.00K$25.69M
    Gross profit$4.21M$1.15M$856.00K$838.00K$1.23M$1.11M$1.45M$2.18M$209.00K$0$591.00K-$1.25M
    Operating income-$39.93M-$43.28M-$50.65M-$48.61M-$53.97M-$53.38M-$52.39M-$44.22M-$54.23M-$55.67M-$48.34M-$68.04M
    Net income-$39.04M-$42.11M-$49.12M-$46.08M-$50.58M-$52.59M-$51.89M-$42.28M-$52.52M-$55.33M-$45.76M-$65.64M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $8.14M by $54.90M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$342.73M$297.51M$193.85M$360.31M$301.86M$54.78M$8.70M
    Current assets$181.29M$211.89M$142.98M$296.62M$270.58M$53.40M$8.70M
    Cash and equivalents$63.03M$182.48M$41.57M$187.62M$185.42M$36.98M$8.65M
    Total liabilities$221.87M$144.36M$60.78M$44.04M$62.30M$21.31M$7.31M
    Short-term debt$8.14M$3.61M$9.28M$11.69M$7.34M$17.52MN/A
    Shareholder equity$120.87M$153.15M$133.07M$316.27M-$156.24M$33.47M$1.39M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$213.85M$249.04M$294.73M$342.73M$385.01M$279.01M$328.16M$297.51M$332.78M$259.70M$311.38M$193.85M
    Total liabilities$205.42M$209.23M$218.03M$221.87M$223.19M$218.15M$221.24M$144.36M$143.28M$63.12M$67.62M$60.78M
    Cash and equivalents$54.89M$47.45M$64.11M$63.03M$71.40M$53.80M$91.88M$182.48M$117.98M$55.60M$94.16M$41.57M
    Shareholder equity$8.44M$39.81M$76.70M$120.87M$161.82M$60.86M$106.92M$153.15M$189.50M$196.59M$243.77M$133.07M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$162.56M-$122.86M-$165.41M-$131.83M-$34.08M-$5.54M-$1.33M
    Capital expenditures$4.53M$7.29M$8.72M$16.09M$4.15M$639.00K$639.00K
    Free cash flow-$167.09M-$130.16M-$174.14M-$147.92M-$38.23M-$6.18M-$1.97M
    Share repurchasesN/AN/AN/A$4.04M$1.09M$20.00KN/A
    Investing cash flow-$108.76M$68.46M$18.71M-$47.10M-$73.63M-$1.06M-$1.06M
    Financing cash flow$151.51M$195.88M$655.00K$181.49M$269.28M$34.93M$9.98M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$36.68M-$41.05M-$42.71M-$37.26M-$35.04M-$41.41M-$48.86M$16.25M-$25.91M-$45.49M-$67.71M-$43.86M
    Capital expenditures$298.00K$46.00K$214.00K$290.00K$247.00K$1.57M$2.42M$1.79M$1.28M$1.90M$2.32M$1.84M
    Free cash flow-$36.98M-$41.09M-$42.92M-$37.55M-$35.29M-$42.98M-$51.28M$14.45M-$27.19M-$47.39M-$70.03M-$45.70M
    Last 12 quarters

    Frequently Asked Questions About PRME

    What is Prime Medicine, Inc. Common Stock's annual revenue?

    Prime Medicine, Inc. Common Stock reported revenue of $4.63M for the fiscal year ended Dec 31, 2025.

    How fast is Prime Medicine, Inc. Common Stock's revenue growing?

    Revenue was up 55.3% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Prime Medicine, Inc. Common Stock profitable?

    No. Prime Medicine, Inc. Common Stock reported net income of -$201.14M for the fiscal year ended Dec 31, 2025, with a net margin of -4342.4%.

    How much free cash flow does PRME generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$162.56M minus capital expenditures of $4.53M produced free cash flow of -$167.09M.

    How much debt does Prime Medicine, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $8.14M and cash and equivalents of $63.03M.